Head to head
Bio-Rad Laboratories vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: BIO · ABT
BIO
Bio-Rad Laboratories
367.92-0.25%
1-year price shape — +24% over the period
Quant Rating C · 61/100
vs
ABT
Abbott Laboratories
98.73+0.58%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories trades cheapest on trailing earnings; Abbott Laboratories pays the highest dividend yield.
| BIO | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 367.92 | 98.73 |
| Change today | -0.25% | +0.58% |
| 1-year return | +24.1% | -24.1% |
| Market cap | $9.84B | $170.84B |
| 52-week range | 236.73 – 396.23 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | 44.81 | 31.95 |
| P/E percentile, own 5-yr range | 94th | 62nd |
| P/B | 1.37 | 3.34 |
| Dividend yield | 0.00% | 2.47% |
| Profitability & growth | ||
| EPS (TTM) | 27.85 | 3.72 |
| Net profit (TTM) | $744.66M | $6.44B |
| Revenue (TTM) | $2.59B | $46.59B |
| Revenue growth (YoY) | -0.1% | +13.0% |
| Gross margin | 51.9% | 56.6% |
| Operating margin | 8.7% | 15.8% |
| Net margin | 8.6% | 11.6% |
| Free cash flow (TTM) | $353.10M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 88.6% | 81.2% |
| Insider activity (12mo) | 33 buy / 17 sell | 36 buy / 12 sell |
| Short interest (% of float) | 3.7% | 1.1% |
| Analyst consensus | 100% buy (1) | 100% buy (14) |
| Analyst price target | $390 (+6%) | $125 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | C (61) | E (15) |
| Company | ||
| Employees | 7,450 | 115,000 |
| Founded | 1952 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.